Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial

Although Staphylococcus aureus is a common cause of bacteremia, treatment options are limited. The need for new therapies is particularly urgent for methicillin-resistant S. aureus bacteremia (SAB). Ceftobiprole is an advanced-generation, broad-spectrum cephalosporin with activity against both methi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamed, Kamal, Engelhardt, Marc, Jones, Mark E, Saulay, Mikael, Holland, Thomas L, Seifert, Harald, Fowler Jr, Vance G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046132/
https://www.ncbi.nlm.nih.gov/pubmed/31918579
http://dx.doi.org/10.2217/fmb-2019-0332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046132/
https://www.ncbi.nlm.nih.gov/pubmed/31918579
http://dx.doi.org/10.2217/fmb-2019-0332

Ejemplares similares